PEPITEM Modulates the Synovial Environment in Immune-Mediated Inflammatory Arthritis to Mitigate Disease Progression

1

PEPITEM is a 14 amino acid immunopeptide that limits leukocyte trafficking and is diminished in patients with immune-mediated inflammatory diseases.
2

Current treatments for rheumatoid arthritis and psoriatic arthritis do not restore endogenous regulatory pathways, leaving a gap in effective management.
3

Patients with rheumatoid arthritis have elevated adiponectin levels, which correlate with disease severity and radiographic erosions.
4

B cells from patients with rheumatoid arthritis fail to respond to adiponectin, resulting in decreased PEPITEM secretion and impaired immune regulation.
5

The study explores the therapeutic efficacy of PEPITEM in murine models of inflammatory arthritis, aiming to modify the synovial microenvironment.

Arthritis & Rheumatology

by Mussarat Wahid, Samuel Kemble, Oladimeji Abudu, Anella Saviano, Christopher Mahony, Jonathan W. Lewis, Thomas A. Nicholson, Anna Schettino, Noemi Marigliano, Kathryn Frost, Jenefa Begum, Alyssa M. Urbanowski, Marion Limo, Rakesh Jha, Sandra Martinez Jarquin, Laleh Pezhman, Abbie E. A. Degan, Amy E. Anderson, Charlotte G. Smith, Armaiti Batki, Holly Adams, Francesco Caso, Raffaele Scarpa, Iain McInnes, Stefan Siebert, Arthur G. Pratt, Andrew Filer, Karim Raza, Adam P. Croft, Myriam Chimen, Felicity de Cogan, G. Ed Rainger, Asif J. Iqbal, Francesco Maione, Helen M. McGettrick
July 1, 2026

1